Xenobiotica

Article	Citations
A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites	22
Formulation of apigenin-loaded solid lipid nanoparticles: characterisation, molecular docking, and anticancer assay	18
One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development	16
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver	13
Academic foreign compound metabolism – ‘ quo vadis ’?	12
Developmental stage and infection status may affect drug distribution in the prostate of rats	11
Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study	10
Apigenin Derivatives as Promising Norovirus RdRp Inhibitors: Insights from In Silico Docking and Molecular Dynamics Studies	9
In vitro hepatic metabolism of the natural product quebecol	9
Diisononyl phthalate down-regulates the expression of antioxidant genes NFE2L2 , TXN , and TXNRD2 , while d	8
Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model	8
Meeting report: oligonucleotide ADME workshop	8
Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2	8
Nrf2 signaling pathway studies in Drosophila melanogaster : parallel roles in human health and insect environmental responses	8
In silico models to predict tubular secretion or reabsorption clearance pathway using physicochemical properties and structural characteristics	8
Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences	7
Metabolic activation of zolmitriptan mediated by CYP2D6	7
Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers	7
Adenine-related compounds modulate UDP-glucuronosyltransferase (UGT) activity in mouse liver microsomes	7
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor	7
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro	7
Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions	7
In vivo evaluation of pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin	7
Arctigenin-induced erythrocyte membrane remodelling is mediated through calcium influx, metabolic collapse, and casein kinase 1α	7
Preparation, characterisation, pharmacokinetics and distribution of esculin microspheres administered via intravitreal injection into rabbit brain	7

Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver	7
Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients	7
Effects of the total flavonoid extracts and the monomers of Daphne genkwa on CYP2C8 activity	7
Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation	7
Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P 1 modulator ponesimod	6
Absorption, distribution, metabolism, and excretion of [14C]TPN729 after oral administration to rats	6
Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics	6
2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A2	6
Defining the enzymes of xenobiotic metabolism – a forlorn hope?	6
Beyond cytotoxic potency: disposition features required to design ADC payload	6
An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds	6
Exploring precision-cut liver slices for comparative xenobiotic metabolism profiling in swine and cattle	6
Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-M	6
Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants	6
Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats	6
Prediction of the neurotoxic mechanisms of the pesticide phorate using network toxicology, molecular docking, and molecular dynamics simulation	6
New era in bioequivalence global harmonization through ICH M13 initiative: critical review on new concepts, alternative approaches for high-risk products	6
Machine learning-driven bioavailability prediction in early-stage drug development: a KNIME-based computational workflow for digital health applications	6
The effect of ARVs on the MEKKK1 gene promoter, inflammatory cytokine expression and signalling in acute treated Jurkat T cells	6
Experimental and computational models to investigate intestinal drug permeability and metabolism	6
Development of eugenol-fortified fisetin-loaded nano-invasomes gel	6
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population	6
Interactions of organophosphorus pesticides with ATP-binding cassette (ABC) drug transporters	5
Metabolism of gartanin in liver microsomes and its modulating effects on cytochrome P450s	5
Mechanism of Black American Ginseng saponins in ameliorating memory dysfunction in aging mice by activating the BDNF/PI3K/AKT/CREB pathway	5
Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation	5
Preface for special issue: “Emerging strategies, technologies, and approaches for the next generation ADCs”	5
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir	5
Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities	5
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective	5
DEC1 negatively regulates CYP2B6 expression by binding to the CYP2B6 promoter region ascribed to IL-6-induced downregulation of CYP2B6 expression in HeLa cells	5
Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications	5
Coptisine modulates the pharmacokinetics of florfenicol by targeting CYP1A2, CYP2C11 and CYP3A1 in the liver and P-gp in the jejunum of rats: a pilot study	5
2-Naphthalenemethanol participates in metabolic activation of 2-methylnaphthalene	5
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities	5
Effectiveness of pain care intervention combined with traditional Chinese medicine care in the perioperative care of patients with urinary stones	5
Species differences in liver microsomal hydrolysis of acyl glucuronide in humans and rats	5
Impact of tectoridin on the pharmacokinetics of florfenicol via targeting cytochrome P450 and P-glycoprotein of rats	5
Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?	5
The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma	5
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human	5
Bioavailability and dose proportionality of a highly lipophilic phenolic antioxidant	5
Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys	5
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species	5
Meeting report of the 3rd European Biotransformation Workshop	5
Sanguinarine-induced proteomic changes in methicillin-resistant Staphylococcus aureus	5
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury	4
Drug-drug interaction between danshensu and irbesartan and its potential mechanism	4
Sodium dodecylbenzene sulphonate (SDBS) present in detergents: action on the gills, skin, and blood of D. rerio fish	4
Metabolic profiling in liver microsomes and mice of E28, a potent FLT3 inhibitor	4

A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate	4
Mirogabalin, a novel α2δ ligand, is not a substrate of LAT1, but of PEPT1, PEPT2, OAT1, OAT3, OCT2, MATE1 and MATE2-K	4
Inorganic mercury pharmacokinetics in man: a hybrid model	4
The impact of CYP3A5 , NR1I2 , and POR polymorphisms on tacrolimus dose-adjusted concentration and clinical	4
Characterisation of seven medications approved for attention-deficit/hyperactivity disorder usingin vitromodels of hepatic metabolism	4
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects	4
Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats	4
How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data	4
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration	4
Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection	4
Meeting report: DMDG peptide and oligonucleotide ADME workshop 2024	4
EP300/HIF-1 pathway: the key to sacubitril valsartan sodium alleviating myocardial hypoxia injury	4
Pharmacokinetics of intranasal drugs, still a missed opportunity?	4
Perspectives on the use of machine learning for ADME prediction at AstraZeneca	4
Study of the urinary metabolites of 17ɑ-methyl-19-nortestosterone in human using gas chromatography – mass spectrometry. Preliminary results	4
Response to the comments raised by Fernando Tricta	4
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)	4
Pharmacokinetics, tissue distribution, plasma protein binding rate and excretion of sinoacutine following intravenous administration in female and male Sprague-Dawley rats	4
Species differences in oxidative metabolism of regorafenib	4
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor	4
Potential influence of interleukin-6 -174G/C gene polymorphism on kidney graft function and tacrolimus dose requirements: five-year follow-up	4
The chlorophenoxy herbicide MCPA: a mechanistic basis for the observed differences in toxicological profile in humans and rats versus dogs	4
Calycosin improves insulin resistance by regulating the hsa-miR-324-3p/AKT pathway to inhibit FOXO3a nuclear transfer	3
Pharmacokinetics of chelerythrine and its metabolite after oral and intramuscular administrations in pigs	3
Bottom-up physiologically based pharmacokinetic modelling for predicting the human pharmacokinetic profiles of the ester prodrug MGS0274 and its active metabolite MGS0008, a metabotropic glutamate 2/3	3
Meeting report: 3rd workshop of the peptide ADME discussion group	3
Investigation on the in vitro metabolism of bicyclol using liver microsomes, hepatocytes and human recombinant cytochrome P450 enzymes	3
Preclinical pharmacokinetics, metabolism, and disposition of NXE0041178, a novel orally bioavailable agonist of the GPR52 receptor with potential for treatment of schizophrenia and related psychiatric	3
Biochemical responses of the mussel Perna perna after exposure to environmental concentrations of the UV filter Benzophenone-3	3
Potential application of mass spectrometry imaging in pharmacokinetic studies	3
Meeting report: DMDG peptide and oligonucleotide ADME workshop 2022	3
N, N -dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation	3
A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism	3
Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma	3
Effect of tubeimoside I on the activity of cytochrome P450 enzymes in human liver microsomes	3
Thank you to reviewers	3
The metabolism of the dual orexin receptor antagonist daridorexant	3
Qualitative and quantitative status of cytochrome P450s after the administration of a liposomal platelet substitute in rat liver	3
Study on the transport and internalisation mechanism of dietary supplement nattokinase in the small intestine using animal and Caco-2 cell monolayer models	3
Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559	3
Role of hesperidin and fresh orange juice in altering the bioavailability of beta-blocker, metoprolol tartrate. An in vivo model	3
Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase	3
Benzophenone-3 (oxybenzone) in zebrafish: histopathological and oxidative stress analysis	3
Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats	3
Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs	3
Metabolites identification and species comparison of Oroxylin A, an anti-cancer flavonoid, in vitro and in vivo by HPLC-Q-TOF-MS/MS	3
Feature-based molecular networking updates the in vitro metabolic characterisation of fenbendazole across species	3
Prediction of pharmacokinetics of an anaplastic lymphoma kinase inhibitor in rat and monkey: application of physiologically based pharmacokinetic model as an alternative tool to minimise animal studie	3
Permethrin disrupts antioxidant defense responses in Litopenaeus vannamei	3
Analysis of the therapeutic potential of astragalin: insights into target interactions and mechanisms	3
Investigation of pharmacokinetic properties of a PEGylated bilirubin nanoparticle in male Sprague-Dawley rats using liquid chromatography-quadrupole time-of-flight mass spectrometry	3
Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs	3
Bidirectional relationship between statins and the gut microbiota: implications for cardiovascular health, diabetes, and cancer	3
Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models	3
Determination of enzymatic kinetics of metabolism of dimethoate and omethoate in rats and humans	3
Metabolism and disposition of zamicastat in rats	2
Regulatory effect of atorvastatin combined with berberine on PI3K/AKT/FoxO1 signaling pathway in rats with hyperlipidaemia	2
The 50th anniversary of the DMDG	2
Exploring ethanol’s toxicity in the oral submucosa: chronic exposure versus abstinence in C57BL/6 mice	2
Justification of widened dissolution specifications of an extended-release product using physiologically based biopharmaceutics modeling	2
Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy	2
In silico analysis of nicotine’s molecular targets in Parkinson’s disease	2
Epifriedelanol enhances adriamycin-induced cytotoxicity towards K562/ADM cells by down regulating of P-gp and MRP2	2
Comprehensive characterization and optimization of Caco-2 cells enabled the development of a miniaturized 96-well permeability assay	2
Evaluation of the non-linearity of NA808 in liver not reflected in plasma using a rat pharmacokinetic study and PBPK modelling	2
Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance	2
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies	2
Meeting report of the second European biotransformation workshop	2
In vitro and in vivo metabolic profiling of PD105, a PI3Kδ inhibitor, using UHPLC-Q-Exactive plus-MS	2
Predictive role of polymorphic variants of phase II drug metabolising enzyme in modulating toxicity in North Indian lung cancer patients undergoing chemotherapy	2
The impact of ibuprofen on valproic acid plasma concentration in pediatric patients	2
A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers	2
The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro	2
Metabolite characterisation of the peptide–drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS	2
The pharmacokinetics of dabigatran in a rat model of hyperlipidaemia induced by poloxamer 407	2
MRM-driven metabolomic workflow for early detection of antibiotic-triggered sub-lethal toxicity using Q-TRAP and zebrafish model	2
Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development	2
Quantitative prediction of OATP1B-mediated drug–drug interactions using endogenous biomarker coproporphyrin I	2
UGT1A1 and UGT1A3 activity and inhibition in human liver and intestinal microsomes and a recombinant UGT system under similar assay conditions using selective substrates and inhibitors	2
Meeting report: DMPK optimisation strategies and quantitative translational PKPD frameworks to predict human PK and efficacious dose of targeted protein degraders	2

Exposure to crack cocaine induces genotoxicity and degenerative changes in multiple organs of Wistar rats	2
Mechanism-based inactivation of cytochrome P450 3A by evodol	2
Use of stable isotope labeled (SIL) antibodies in cassette dosing to improve pharmacokinetics screening efficiency of ADCs with novel cytotoxic payloads	2
Metabolic conversion of β-pinene to β-ionone in rats	2
In vitro and in vivo studies on the metabolism and pharmacokinetics of the selective gut microbial β-glucuronidase targeting compound Inh 1	2
CYP-catalysed cycling of clozapine and clozapine- N -oxide promotes the generation of reactive oxygen species in vitro	2
Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation	2
Prediction of the liver safety profile of a first-in-class myeloperoxidase inhibitor using quantitative systems toxicology modeling	2
Combination of losartan and puerarin induced pharmacokinetic interaction in hypertension rats enhances the antihypertensive effect of losartan	2
Metabolic exhaustion and casein kinase 1α drive deguelin-induced premature red blood cell death	2
In vitro anti-glucocorticoid osteoporosis effect of Serfurosterone A and its intestinal absorption characteristics	2
Fluoxetine as an antidepressant agent induces directly deleterious effects on rat isolated pancreatic mitochondria: ameliorative role of betanin	2
Synthesis and evaluation of indomethacin prodrugs with a diester structure that are metabolically activated by human carboxylesterases	2
The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A4	2
Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and	2
Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer	2
Tree shrew cytochrome P450 2E1 is a functional enzyme that metabolises chlorzoxazone and p -nitrophenol	2
Effects of ABCG2 421C > A genetic polymorphism on the pharmacokinetics of rivaroxaban in healthy Chinese subjects	2
A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist	2
Chronic Toxoplasma infection affects gene expression of drug-metabolizing enzymes in mouse liver	2